Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management

Journal of Allergy and Clinical Immunology

Volumn 123, Issue 6, 2009, Pages

  Hesterberg, Paul E ^a   Banerji, Aleena ^a   Oren, Eyal ^a   Penson, Richard T ^a   Krasner, Carolyn N ^a   Seiden, Michael V ^b   Wong, Johnson T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

carboplatin; Desensitization; drug allergy; hypersensitivity; ovarian cancer; skin testing

Indexed keywords

CARBOPLATIN; DESLORATADINE; DEXAMETHASONE; FEXOFENADINE; HISTAMINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DESENSITIZATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN TEST; TREATMENT OUTCOME; VOMITING; IMMUNOLOGY; MIDDLE AGED; OVARY TUMOR; RISK;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RISK; SKIN TESTS;

EID: 67649171726     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.02.042     Document Type: Article

References (33)

1. Cancer facts and figures 2005 (2005), American Cancer Society, Atlanta
2. du Bois A., Luck H.J., Meier W., Adams H.P., Mobus V., Costa S., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 (2003) 1320-1329
3. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
4. Markman M., Kennedy A., Webster K., Elson P., Peterson G., Kulp B., et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17 (1999) 1141
5. Weidmann B., Mulleneisen N., Bojko P., and Niederle N. Hypersensitivity reactions to carboplatin: report of two patients, review of the literature, and discussion of diagnostic procedures and management. Cancer 73 (1994) 2218-2222
6. Sliesoraitis S., and Chikhale P.J. Carboplatin hypersensitivity. Int J Gynecol Cancer 15 (2005) 13-18
7. Zanotti K.M., Rybicki L.A., Kennedy A.W., Belinson J.L., Webster K.D., Kulp B., et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19 (2001) 3126-3129
8. Sood A.K., Gelder M.S., Huang S.W., and Morgan L.S. Anaphylaxis to carboplatin following multiple previous uncomplicated courses. Gynecol Oncol 57 (1995) 131-132
9. Zweizig S., Roman L.D., and Muderspach L.I. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 53 (1994) 121-122
10. Tonkin K.S., Rubin P., and Levin L. Carboplatin hypersensitivity: case reports and review of the literature. Eur J Cancer 29A (1993) 1356-1357
11. Chang S.M., Fryberger S., Crouse V., Tilford D., and Prados M.D. Carboplatin hypersensitivity in children: a report of five patients with brain tumors. Cancer 75 (1995) 1171-1175
12. Dizon D.S., Dupont J., Anderson S., Sabbatini P., Hummer A., Aghajanian C., et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel: the Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 91 (2003) 584-590
13. Morgan J.S., Adams M., and Mason M.D. Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 30A (1994) 1205-1206
14. Polyzos A., Tsavaris N., Kosmas C., Arnaouti T., Kalahanis N., Tsigris C., et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61 (2001) 129-133
15. Rose P.G., Fusco N., Fluellen L., and Rodriguez M. Carboplatin hypersensitivity reactions in patients with ovarian and peritoneal carcinoma. Int J Gynecol Cancer 8 (1998) 365-368
16. Jones R., Ryan M., and Friedlander M. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol 89 (2003) 112-115
17. Kandel M.J., Loehr A., Harter P., Traut A., Gnauert K., and du Bois A. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. Int J Gynecol Cancer 15 (2005) 780-784
18. Shukunami K., Kurokawa T., Kubo M., Kaneshima M., Kamitani N., and Kotsuji F. Hypersensitivity reaction to carboplatin during treatment for ovarian cancer: successful resolution by replacement with cisplatin. Tumori 85 (1999) 297-298
19. Gutierrez M., Pautier P., and Lhomme C. Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to carboplatin. J Clin Oncol 20 (2002) 353
20. Fukui M., Penson R.T., Krishna V., Seiden M.V., Krasner C.N., and Wong J.T. Carboplatin and cisplatin hypersensitivity-pattern, potential mechanism, and desensitization. J Allergy Clin Immunol 113 (2004) S72
21. Callahan M.B., Lachance J.A., Stone R.L., Kelsey J., Rice L.W., and Jazaeri A.A. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol 197 (2007) 199 e1-4discussion e4-5
22. Broome C.B., Schiff R.I., and Friedman H.S. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 26 (1996) 105-110
23. Confino-Cohen R., Fishman A., Altaras M., and Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer 104 (2005) 640-643
24. Lee C.W., Matulonis U.A., and Castells M.C. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 99 (2005) 393-399
25. Robinson J.B., Singh D., Bodurka-Bevers D.C., Wharton J.T., Gershenson D.M., and Wolf J.K. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 82 (2001) 550-558
26. Rose P.G., Fusco N., Smrekar M., Mossbruger K., and Rodriguez M. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 89 (2003) 429-433
27. Lee C.W., Matulonis U.A., and Castells M.C. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 95 (2004) 370-376
28. Goldberg A., Confino-Cohen R., Fishman A., Beyth Y., and Altaras M. A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol 98 (1996) 841-843
29. Markman M., Hsieh F., Zanotti K., Webster K., Peterson G., Kulp B., et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol 130 (2004) 25-28
30. Markman M., Zanotti K., Peterson G., Kulp B., Webster K., and Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 21 (2003) 4611-4614
31. Wong J.T., Ripple R.E., MacLean J.A., Marks D.R., and Bloch K.J. Vancomycin hypersensitivity: synergism with narcotics and "desensitization" by a rapid continuous intravenous protocol. J Allergy Clin Immunol 94 (1994) 189-194
32. Windom H.H., McGuire III W.P., Hamilton R.G., and Adkinson Jr. N.F. Anaphylaxis to carboplatin-a new platinum chemotherapeutic agent. J Allergy Clin Immunol 90 (1992) 681-683
33. Lin R.Y., Schwartz L.B., Curry A., Pesola G.R., Knight R.J., Lee H.S., et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 106 (2000) 65-71